Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025)
Neumora Therapeutics' quarterly Long-Term Debt Issuances came in at $38.9 million in Q4 2025, up 28702.21% quarter-over-quarter from -$136000.0 in Q3 2025.
Neumora Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $38.9 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $38.9 million; the trailing twelve-month figure through Dec 2025 stood at $38.8 million (changed N/A YoY), and the FY2025 full-year result was $57.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $38.9 million, up from -$136000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $38.9 million in Q4 2025, with the low at -$136000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38.90 Mn |
| Dec 31, 2025 | 38.90 Mn |
| Sep 30, 2025 | -136,000.00 |
| Sep 30, 2025 | -136,000.00 |